Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | PPARD | Q03181 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782708 | 1.00 | PPARG (1.00) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188336 | 0.92 | PPARG (0.85) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188281 | 0.90 | PPARG (1.00) | PPARGCYP2C8PTGS2MAPTTP53 | |
| SCHEMBL29612205 | 0.86 | PPARG (0.83) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188338 | 0.86 | PPARG (0.82) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188323 | 0.86 | PPARG (0.84) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188341 | 0.85 | PPARG (0.79) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188307 | 0.85 | PPARG (0.82) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188321 | 0.85 | PPARG (0.79) | PPARGCYP2C8PTGS2MAPTNR1I2 | |
| SCHEMBL27188315 | 0.85 | PPARG (0.79) | PPARGCYP2C8PTGS2MAPTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | claimed |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | PPARG 1/4885CYP2C8 839/4885PTGS2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.